Total Payments
$620,206
2024 Payments
$72,571
Companies
41
Transactions
1,348
Medicare Patients
17,052
Medicare Billing
$2.2M
Payment Breakdown by Category
Other$546,545 (88.1%)
Food & Beverage$32,605 (5.3%)
Travel$31,014 (5.0%)
Consulting$9,915 (1.6%)
Education$128.51 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $510,005 | 255 | 82.2% |
| Honoraria | $36,540 | 14 | 5.9% |
| Food and Beverage | $32,605 | 934 | 5.3% |
| Travel and Lodging | $31,014 | 111 | 5.0% |
| Consulting Fee | $9,915 | 13 | 1.6% |
| Education | $128.51 | 21 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $170,647 | 281 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $84,667 | 159 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $81,806 | 249 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $65,681 | 89 | $0 (2024) |
| Amgen Inc. | $59,462 | 112 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $41,429 | 53 | $0 (2024) |
| PFIZER INC. | $34,753 | 65 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $26,521 | 79 | $0 (2024) |
| Lilly USA, LLC | $17,603 | 19 | $0 (2024) |
| AstraZeneca UK Limited | $13,338 | 7 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $72,571 | 201 | Lexicon Pharmaceuticals, Inc. ($41,301) |
| 2023 | $46,311 | 146 | Janssen Pharmaceuticals, Inc ($20,933) |
| 2022 | $40,831 | 127 | Janssen Pharmaceuticals, Inc ($14,295) |
| 2021 | $75,325 | 166 | Janssen Pharmaceuticals, Inc ($31,698) |
| 2020 | $59,807 | 151 | Janssen Pharmaceuticals, Inc ($22,945) |
| 2019 | $131,310 | 236 | Janssen Pharmaceuticals, Inc ($30,468) |
| 2018 | $116,725 | 178 | Novartis Pharmaceuticals Corporation ($33,111) |
| 2017 | $77,327 | 143 | Novartis Pharmaceuticals Corporation ($30,916) |
All Payment Transactions
1,348 individual payment records from CMS Open Payments — Page 1 of 54
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $23.08 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 12/17/2024 | Alnylam Pharmaceuticals Inc. | ONPATTRO (Drug) | Food and Beverage | In-kind items and services | $34.39 | General |
| Category: Genetic Disease | ||||||
| 12/17/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $19.72 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/13/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Boston Scientific Corporation | WATCHDOG (Device) | Food and Beverage | In-kind items and services | $31.31 | General |
| Category: WATCHDOG_IC | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $300.00 | General |
| 12/04/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 12/03/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $17.74 | General |
| Category: Cardiovascular | ||||||
| 12/02/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $880.00 | General |
| Category: DIABETES | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $25.93 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/23/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $19.17 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/20/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: Obesity | ||||||
| 11/19/2024 | E.R. Squibb & Sons, L.L.C. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,232.00 | General |
| 11/19/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: Cardiology | ||||||
| 11/18/2024 | Sensible Medical Innovations Inc | ReDS system (Device) | Food and Beverage | Cash or cash equivalent | $40.81 | General |
| Category: ReDS system | ||||||
| 11/13/2024 | SCPHARMACEUTICALS INC. | FUROSCIX (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Cardiology | ||||||
| 11/12/2024 | MEDICOMP INC | TELEPATCH CARDIAC MONITOR (Device) | Food and Beverage | In-kind items and services | $21.71 | General |
| Category: CARDIOLOGY | ||||||
| 11/12/2024 | Esperion Therapeutics, Inc. | NEXLETOL (Drug) | Food and Beverage | In-kind items and services | $13.96 | General |
| Category: ANTILIPEMIC AGENTS | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $28.15 | General |
| Category: Cardiovascular | ||||||
| 11/04/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $29.24 | General |
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $32.14 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/29/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $2.03 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 4,523 | 8,175 | $2.3M | $617,946 |
| 2022 | 26 | 4,478 | 7,696 | $2.2M | $589,390 |
| 2021 | 27 | 4,077 | 7,021 | $2.0M | $552,815 |
| 2020 | 28 | 3,974 | 7,126 | $1.5M | $394,339 |
Total Patients
17,052
Total Services
30,018
Medicare Billing
$2.2M
Procedure Codes
109
All Medicare Procedures & Services
109 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 990 | 1,529 | $527,505 | $144,770 | 27.4% |
| 33285 | Insertion of heart rhythm monitor under skin | Office | 2023 | 23 | 23 | $316,989 | $86,101 | 27.2% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 222 | 222 | $341,658 | $82,112 | 24.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 451 | 470 | $312,585 | $72,448 | 23.2% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 185 | 368 | $68,080 | $54,343 | 79.8% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 79 | 617 | $37,020 | $25,993 | 70.2% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 1,009 | 1,620 | $108,540 | $18,090 | 16.7% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 103 | 394 | $39,400 | $17,199 | 43.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 168 | 217 | $51,429 | $15,291 | 29.7% |
| 78803 | Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | Office | 2023 | 46 | 46 | $48,300 | $13,629 | 28.2% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 78 | 618 | $53,766 | $12,314 | 22.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 95 | 95 | $48,450 | $11,922 | 24.6% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 229 | 230 | $61,410 | $11,815 | 19.2% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 303 | 310 | $39,990 | $9,489 | 23.7% |
| 99496 | Transitional care management services for problem of high complexity | Office | 2023 | 41 | 41 | $31,734 | $9,403 | 29.6% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 102 | 290 | $29,000 | $5,212 | 18.0% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 85 | 87 | $36,105 | $4,739 | 13.1% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 76 | 202 | $19,998 | $4,716 | 23.6% |
| 93793 | Anticoagulant management of patient taking warfarin | Office | 2023 | 19 | 505 | $20,200 | $4,514 | 22.3% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 49 | 54 | $12,312 | $3,523 | 28.6% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 31 | 92 | $17,480 | $2,395 | 13.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 14 | 14 | $9,100 | $2,371 | 26.1% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 11 | 12 | $7,020 | $2,048 | 29.2% |
| 93291 | Evaluation of cardiac rhythm monitor system | Office | 2023 | 27 | 28 | $3,624 | $1,130 | 31.2% |
| 93279 | Programming of single lead pacemaker system | Office | 2023 | 16 | 20 | $3,690 | $1,102 | 29.9% |
About Dr. John Kalin, MD
Dr. John Kalin, MD is a Cardiovascular Disease healthcare provider based in Hyannis, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1295783447.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Kalin, MD has received a total of $620,206 in payments from pharmaceutical and medical device companies, with $72,571 received in 2024. These payments were reported across 1,348 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($510,005).
As a Medicare-enrolled provider, Kalin has provided services to 17,052 Medicare beneficiaries, totaling 30,018 services with total Medicare billing of $2.2M. Data is available for 4 years (2020–2023), covering 109 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Hyannis, MA
- Active Since 05/04/2006
- Last Updated 11/09/2011
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1295783447
Products in Payments
- XARELTO (Drug) $170,676
- ELIQUIS (Drug) $96,341
- ENTRESTO (Drug) $81,211
- JARDIANCE (Drug) $72,641
- Repatha (Biological) $59,372
- Inpefa (Drug) $41,273
- FARXIGA (Drug) $26,039
- BRILINTA (Drug) $13,694
- PRADAXA (Drug) $10,623
- LifeVest (Device) $7,954
- Vascepa (Drug) $6,882
- CAMZYOS (Drug) $6,777
- WATCHMAN (Device) $4,109
- YOSPRALA (Drug) $1,050
- LEQVIO (Drug) $595.72
- Micra (Device) $562.98
- VERQUVO (Drug) $474.01
- ONPATTRO (Drug) $346.53
- FUROSCIX (Drug) $258.43
- Kerendia (Drug) $244.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Hyannis
Michael Mecley, Md, MD
Cardiovascular Disease — Payments: $15,257
Cardiovascular Disease $15,257
Dr. Peter Chiotellis, M.d, M.D
Cardiovascular Disease — Payments: $12,099
Cardiovascular Disease $12,099
Michael Levangie, Md, MD
Cardiovascular Disease — Payments: $10,667
Cardiovascular Disease $10,667
Adam Mohmand-Borkowski, M.d, M.D
Cardiovascular Disease — Payments: $9,810
Cardiovascular Disease $9,810
Dr. Philip Chiotellis, M.d, M.D
Cardiovascular Disease — Payments: $5,543
Cardiovascular Disease $5,543
Luke Daley, Md, MD
Cardiovascular Disease — Payments: $4,051
Cardiovascular Disease $4,051